UnknownPHASE1, PHASE2NCT00955630
Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
Studying Histoplasmosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Retina Associates of Kentucky
- Principal Investigator
- John Kitchens, MDRetina Associates of Kentucky
- Intervention
- ranibizumab(drug)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2009
Study locations (1)
- Retina Associates of Kentucky, Lexington, Kentucky, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00955630 on ClinicalTrials.govOther trials for Histoplasmosis
Additional recruiting or active studies for the same condition.